For decades, Alzheimer’s researchers have watched the same frustrating pattern: the brain’s immune cells detect a threat, mount an inflammatory response, and then never stand down. That chronic, self-sustaining inflammation chews through neurons long after the original amyloid plaques have formed, and no approved drug directly addresses it. Now, a team led by neuroscientist Stuart Lipton at Scripps Research has identified the precise molecular event that keeps that inflammatory fire lit: a single chemical modification on one amino acid of a protein called STING.
Their findings, published in Cell Chemical Biology in spring 2026, show that a redox-driven modification called S-nitrosylation locks STING into a pro-inflammatory state in the brains of Alzheimer’s mice. Block that modification at its specific location, a cysteine residue labeled Cys148, and the downstream neural damage drops. The discovery suggests a new class of treatment: one that cools chronic brain inflammation without dismantling the immune defenses STING provides against viruses and tumors elsewhere in the body.
Why neuroinflammation is the next frontier
The FDA’s recent approvals of anti-amyloid antibodies, lecanemab (Leqembi) and donanemab (Kisunla), marked a turning point in Alzheimer’s treatment. But the clinical gains have been modest: these drugs slow cognitive decline by roughly 25 to 35 percent in early-stage patients, and they carry risks of brain swelling and microbleeds. A growing number of researchers argue that clearing amyloid plaques addresses only part of the problem. The other part is the inflammatory cascade that plaques set in motion, driven largely by microglia, the brain’s resident immune cells.
Microglia are supposed to detect threats, clean up debris, and return to a resting state. In Alzheimer’s, they get stuck in attack mode. They release inflammatory molecules that damage synapses and kill neurons, creating a cycle of destruction that feeds on itself. The question that has dogged the field is: what keeps microglia locked in that activated state? Lipton’s team now points to STING, and specifically to what happens when a nitric oxide-derived chemical group attaches to Cys148.
What the Scripps team found
STING (Stimulator of Interferon Genes) is best known for its role in detecting foreign DNA and triggering antiviral immune responses. But it also responds to signals released by damaged cells, including the kind of cellular debris that accumulates in neurodegenerative disease. Under normal conditions, STING activates briefly and then cycles off. The Scripps study shows that S-nitrosylation at Cys148 jams that off-switch, trapping STING in its active, inflammation-promoting configuration.
In Alzheimer’s model mice, the team demonstrated that preventing the Cys148 modification reduced markers of neural damage. Critically, this approach differs from simply deleting STING entirely. Rather than removing a protein the body needs for infection defense and cancer surveillance, it targets one specific chemical event on one residue, a scalpel rather than a sledgehammer.
Independent work from other labs reinforces the broader case against STING in Alzheimer’s. A separate group showed that genetically knocking out STING in mice engineered to develop Alzheimer’s-like pathology altered amyloid-beta deposition and dampened microglial activation, as detailed in a knockout study published in a separate journal. Pharmacologic evidence points the same direction: research in a Nature Portfolio journal demonstrated that inhibiting STING with small molecules mitigates microglial dysfunction and multiple Alzheimer’s-related pathologies in model systems. And a high-profile Nature paper showed that the STING inhibitor H-151 suppresses pro-inflammatory gene activity, linking the broader cGAS-STING signaling axis to aging-associated inflammation and neurodegeneration.
When genetic deletion, broad pharmacologic inhibition, and now a residue-specific modification all converge on the same protein and the same biological outcome, the collective evidence carries substantially more weight than any single experiment.
The gap between mice and patients
Every result described above comes from mouse models. No published study has yet confirmed that S-nitrosylation at Cys148 occurs at meaningful levels in human Alzheimer’s brain tissue or in human iPSC-derived microglia. This is the single biggest uncertainty hanging over the discovery.
There is reason for cautious optimism on this front. Lipton’s lab has spent years documenting S-nitrosylation of other proteins in postmortem human Alzheimer’s brains, establishing that this type of modification is not just a mouse phenomenon. But confirming it specifically on STING at Cys148 in patient tissue is a different experiment, and it has not been published.
The translation gap has humbled Alzheimer’s research before. More than 200 drug candidates that showed promise in mice have failed in human trials over the past two decades, many because the biology did not transfer cleanly across species. Until the Cys148 finding is validated in human samples, its clinical relevance remains a strong hypothesis rather than a confirmed fact.
Selectivity, safety, and timing
Even if the modification proves relevant in humans, targeting it safely will be a challenge. The existing pharmacologic tool, H-151, blocks STING activity broadly across the body. That is a problem because STING plays well-documented roles in antiviral defense and tumor surveillance. Suppressing it systemically could leave patients vulnerable to infections or cancers, a tradeoff that would be difficult to justify in a slowly progressing disease like Alzheimer’s.
The Cys148-selective approach proposed by the Scripps team could, in theory, sidestep that problem by disabling only the runaway inflammatory loop while leaving STING’s other functions intact. But no head-to-head comparison between a Cys148-selective agent and a global inhibitor has been published in any tissue, let alone in the central nervous system. Designing a drug that distinguishes between one chemical modification on one residue and the protein’s normal activity is a formidable medicinal chemistry challenge.
Timing adds another layer of uncertainty. The mouse experiments focused on animals with established pathology, where plaques and microglial activation were already present. Whether Cys148 S-nitrosylation is an early event that helps initiate the inflammatory cascade, a mid-stage amplifier, or a late consequence of broader damage remains unknown. The answer matters for treatment strategy: if the switch is mainly active late in disease, targeting it might slow progression but would not prevent onset.
No publicly available statements from the Scripps team address therapeutic timelines or off-target safety profiles. Federal grant records on NIH RePORTER confirm that NIH funding supports related work in Lipton’s lab, but specific milestones tied to moving this discovery toward a first-in-human trial have not been disclosed.
What this changes about how we think about Alzheimer’s
The most grounded takeaway from this work is conceptual, not clinical. For years, neuroinflammation in Alzheimer’s has been treated as a diffuse, almost atmospheric phenomenon: the brain is inflamed, and that is bad, but there has been no clear molecular handle to grab. The Scripps discovery and its supporting studies argue that the inflammatory response is not just a fog. It has specific, identifiable control points, molecular switches on key immune proteins that can be individually toggled.
That reframing matters regardless of whether Cys148 itself becomes a drug target. It shifts the research conversation from “how do we reduce inflammation generally” to “which specific modifications on which proteins are holding the inflammatory response in its active state, and can we reverse them one by one.” That is a more tractable question, and it opens the door to precision approaches that the field has lacked.
If future studies confirm the same modification in human brains and demonstrate that it can be safely and selectively reversed, STING could graduate from a mechanistic insight to a genuine therapeutic entry point. For the roughly 7 million Americans living with Alzheimer’s and the millions more worldwide, a treatment that quiets the brain’s self-destructive immune response without compromising the body’s defenses would address a need that today’s approved drugs do not touch.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
